Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
LAUREL COUNTY, Ky. (WYMT) - It has been one month since one Laurel County man was shot to death in his home by London Police. Community members are set to honor the life of Doug Harless at 6:30 pm. on ...
President Donald Trump has issued a “full and unconditional pardon” to Washington, DC, police lieutenant Andrew Zabavsky and ...
Hundreds of immigrants rights supporters gathered in Los Angeles to oppose the Trump administration's mass deportation ...
Hosted on MSN1d
Vigil held to honor Monterey Park mass shooting victimsThe city of Monterey Park hosted a candlelight vigil Tuesday night to mark the second anniversary of a mass shooting in the ...
SAN ANTONIO - An emotional day for the loved ones of a one-year-old and teacher killed in a crash at a school on the Far ...
As the Trump administration begins to carry out promises to tighten immigration enforcement, some New Hampshire faith ...
The community remembered the life of a devoted animal rescuer who died suddenly after a crash in northeast El Paso.
The Arkansas Martin Luther King. Jr. Commission will be hosting a Legacy With Candlelight Vigil, Fireworks Spectacular in ...
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback